RecruitingNCT05392881
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
Sponsor
University of Kansas Medical Center
Enrollment
1,000 participants
Start Date
Aug 9, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
- The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
- The participant is ≥ 18 years of age.
- The participant has signed an approved consent for this study (living patients only)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05392881
Related Trials
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
NCT076130991 location
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia
NCT075126871 location
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
NCT075610341 location
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT075169511 location